Skip to content

25 hydroxyvitamin D levels predict the efficacy of vitolizumab in the treatment of CD patients

25 hydroxyvitamin D levels predict the efficacy of vitolizumab in the treatment of CD patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096398
Enrollment
Unknown
Registered
2025-01-22
Start date
2025-01-22
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn‘s disease

Interventions

Vitamin D exposure group:None

Sponsors

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.>18 years old; 2.Meet the diagnosis and treatment standards of Crohn's disease patients, and refer to the Guidelines for the Diagnosis and Treatment of Crohn's Disease in China (2023 · Guangzhou). 3.Use VDZ for the first time; 4.Patients with baseline 25-hydroxyvitamin D levels recorded (before first VDZ treatment);

Exclusion criteria

Exclusion criteria: 1.<18 years old; 2.Pregnancy; 3.A history of vitamin D use within 3 months prior to treatment with vitolizumab; 4.A history of thyroid disease; 5.Severe liver and kidney dysfunction; 6.Patients with gastrointestinal surgery unrelated to IBD; 7.Patients treated with a second biologic agent during treatment 8.Patients with intestinal Behcet disease and intestinal tuberculosis can not be distinguished;

Design outcomes

Primary

MeasureTime frame
CDAI;

Countries

China

Contacts

Public ContactQian Cao

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

caoq@srrsh.com+86 571 86006186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026